Current strategies against persistent human papillomavirus infection (Review)

International Journal of Oncology
Yu LiuXiaorong Qi

Abstract

Human papillomavirus (HPV) is the most common sexually transmitted infection, exhibiting a tropism for the epidermis and mucosae. The link between persistent HPV infection and malignancies involving the anogenital tract as well as the head and neck has been well‑established, and it is estimated that HPV‑related cancers involving various anatomical sites account for 4.5% of all human cancers. Current prophylactic vaccines against HPV have enabled the prevention of associated malignancies. However, the sizeable population base of current infection in whom prophylactic vaccines are not applicable, certain high‑risk HPV types not included in vaccines, and the vast susceptible population in developing countries who do not have access to the costly prophylactic vaccines, put forward an imperative need for effective therapies targeting persistent infection. In this article, the life cycle of HPV, the mechanisms facilitating HPV evasion of recognition and clearance by the host immune system, and the promising therapeutic strategies currently under investigation, particularly antiviral drugs and therapeutic vaccines, are reviewed.

References

Jun 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·M DürstH zur Hausen
Feb 28, 1995·Proceedings of the National Academy of Sciences of the United States of America·S Jeon, P F Lambert
Mar 1, 1997·Journal of Virology·M EvanderN A McMillan
Jun 20, 1998·Experimental Cell Research·H NakajimaS Horinouchi
Jul 8, 1998·Proceedings of the National Academy of Sciences of the United States of America·S Gross-MesilatyA Ciechanover
Jan 20, 1999·Proceedings of the National Academy of Sciences of the United States of America·T MaJ W Harper
Apr 21, 1999·International Journal of Cancer. Journal International Du Cancer·S HallezO Leo
Jul 28, 1999·International Immunology·F A Le GalN Rouas-Freiss
Jul 30, 1999·Journal of Medicinal Chemistry·T SuzukiO Nakanishi
Nov 26, 1999·Journal of the American Academy of Dermatology·K R BeutnerM L Owens
May 8, 2000·International Journal of Cancer. Journal International Du Cancer·E Y ChangT Wu
Jan 11, 2001·Journal of Virology·T GiroglouM Sapp
May 30, 2001·Transplantation Proceedings·R Marchal-Bras-GoncalvesJ Guillet
Oct 24, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·M EvansS Man
Feb 2, 2002·Applied and Environmental Microbiology·L G Bermúdez-HumaránYves Le Loir
Mar 13, 2002·Cancer Letters·Soo-Jong UmJong-Sup Park
Mar 26, 2002·Cancer Letters·Liliana VitaliVictor Idoyaga Vargas
Jun 28, 2002·Virus Genes·Van G WilsonDandapani Rangasamy
Aug 27, 2002·The Journal of Infectious Diseases·Anna R GiulianoKenneth Hatch
Dec 4, 2002·The Journal of Antimicrobial Chemotherapy·Luis M Schang
Feb 7, 2003·The New England Journal of Medicine·Nubia MuñozUNKNOWN International Agency for Research on Cancer Multicenter Cervical Cancer Study Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Related Papers

Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases
Chunping Ao, Kang Zeng
Dermatologic Clinics
Mathijs H BrentjensStephen K Tyring
Drug and Therapeutics Bulletin
BMJ Group
© 2021 Meta ULC. All rights reserved